Anushri Chitkara1, Ines Mesa-Eguiagaray1, Sarah H Wild1, Peter S Hall1,2, David A Cameron1,2, Andrew H Sims2, Jonine D Figueroa3,4. 1. Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, EH8 9AG, UK. 2. Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, EH4 2XU, UK. 3. Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, EH8 9AG, UK. jonine.figueroa@ed.ac.uk. 4. Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, EH4 2XU, UK. jonine.figueroa@ed.ac.uk.
Abstract
BACKGROUND: The aetiology of breast cancers diagnosed ≤ 50 years of age remains unclear. We aimed to compare reproductive risk factors between molecular subtypes of breast cancer, thereby suggesting possible aetiologic clues, using routinely collected cancer registry and maternity data in Scotland. METHODS: We conducted a cross-sectional study of 4108 women aged ≤ 50 years with primary breast cancer diagnosed between 2009 and 2016 linked to maternity data. Molecular subtypes of breast cancer were defined using immunohistochemistry (IHC) tumour markers, oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2), and tumour grade. Age-adjusted polytomous logistic regression models were used to estimate odds ratios (OR) and 95% confidence intervals (CI) for the association of number of births, age at first birth and time since last birth with IHC-defined breast cancer subtypes. Luminal A-like was the reference compared to luminal B-like (HER2-), luminal B-like (HER2+), HER2-overexpressed and triple-negative breast cancer (TNBC). RESULTS: Mean (SD) for number of births, age at first birth and time since last birth was 1.4 (1.2) births, 27.2 (6.1) years and 11.0 (6.8) years, respectively. Luminal A-like was the most common subtype (40%), while HER2-overexpressed and TNBC represented 5% and 15% of cases, respectively. Larger numbers of births were recorded among women with HER2-overexpressed and TNBC compared with luminal A-like tumours (> 3 vs 0 births, OR 1.87, 95%CI 1.18-2.96; OR 1.44, 95%CI 1.07-1.94, respectively). Women with their most recent birth > 10 years compared to < 2 years were less likely to have TNBC tumours compared to luminal A-like (OR 0.63, 95%CI 0.41-0.97). We found limited evidence for differences by subtype with age at first birth. CONCLUSION: Number of births and time since last birth differed by molecular subtypes of breast cancer among women aged ≤ 50 years. Analyses using linked routine electronic medical records by molecularly defined tumour pathology data can be used to investigate the aetiology and prognosis of cancer.
BACKGROUND: The aetiology of breast cancers diagnosed ≤ 50 years of age remains unclear. We aimed to compare reproductive risk factors between molecular subtypes of breast cancer, thereby suggesting possible aetiologic clues, using routinely collected cancer registry and maternity data in Scotland. METHODS: We conducted a cross-sectional study of 4108 women aged ≤ 50 years with primary breast cancer diagnosed between 2009 and 2016 linked to maternity data. Molecular subtypes of breast cancer were defined using immunohistochemistry (IHC) tumour markers, oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2), and tumour grade. Age-adjusted polytomous logistic regression models were used to estimate odds ratios (OR) and 95% confidence intervals (CI) for the association of number of births, age at first birth and time since last birth with IHC-defined breast cancer subtypes. Luminal A-like was the reference compared to luminal B-like (HER2-), luminal B-like (HER2+), HER2-overexpressed and triple-negative breast cancer (TNBC). RESULTS: Mean (SD) for number of births, age at first birth and time since last birth was 1.4 (1.2) births, 27.2 (6.1) years and 11.0 (6.8) years, respectively. Luminal A-like was the most common subtype (40%), while HER2-overexpressed and TNBC represented 5% and 15% of cases, respectively. Larger numbers of births were recorded among women with HER2-overexpressed and TNBC compared with luminal A-like tumours (> 3 vs 0 births, OR 1.87, 95%CI 1.18-2.96; OR 1.44, 95%CI 1.07-1.94, respectively). Women with their most recent birth > 10 years compared to < 2 years were less likely to have TNBC tumours compared to luminal A-like (OR 0.63, 95%CI 0.41-0.97). We found limited evidence for differences by subtype with age at first birth. CONCLUSION: Number of births and time since last birth differed by molecular subtypes of breast cancer among women aged ≤ 50 years. Analyses using linked routine electronic medical records by molecularly defined tumour pathology data can be used to investigate the aetiology and prognosis of cancer.
Authors: Li Tao; Laura Chu; Lisa I Wang; Lisa Moy; Melissa Brammer; Chunyan Song; Marjorie Green; Allison W Kurian; Scarlett L Gomez; Christina A Clarke Journal: Cancer Causes Control Date: 2016-08-05 Impact factor: 2.506
Authors: Julie Horn; Signe Opdahl; Monica J Engstrøm; Pål R Romundstad; Steinar Tretli; Olav A Haugen; Anna M Bofin; Lars J Vatten; Bjørn Olav Åsvold Journal: Cancer Causes Control Date: 2014-05-01 Impact factor: 2.506
Authors: C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein Journal: Nature Date: 2000-08-17 Impact factor: 49.962
Authors: Huiyan Ma; Yaping Wang; Jane Sullivan-Halley; Linda Weiss; Polly A Marchbanks; Robert Spirtas; Giske Ursin; Ronald T Burkman; Michael S Simon; Kathleen E Malone; Brian L Strom; Jill A McDonald; Michael F Press; Leslie Bernstein Journal: Cancer Res Date: 2010-01-12 Impact factor: 12.701
Authors: Olivier Brouckaert; Anja Rudolph; Annouschka Laenen; Renske Keeman; Manjeet K Bolla; Qin Wang; Adelheid Soubry; Hans Wildiers; Irene L Andrulis; Volker Arndt; Matthias W Beckmann; Javier Benitez; Carl Blomqvist; Stig E Bojesen; Hiltrud Brauch; Paul Brennan; Hermann Brenner; Georgia Chenevix-Trench; Ji-Yeob Choi; Sten Cornelissen; Fergus J Couch; Angela Cox; Simon S Cross; Kamila Czene; Mikael Eriksson; Peter A Fasching; Jonine Figueroa; Henrik Flyger; Graham G Giles; Anna González-Neira; Pascal Guénel; Per Hall; Antoinette Hollestelle; John L Hopper; Hidemi Ito; Michael Jones; Daehee Kang; Julia A Knight; Veli-Matti Kosma; Jingmei Li; Annika Lindblom; Jenna Lilyquist; Artitaya Lophatananon; Arto Mannermaa; Siranoush Manoukian; Sara Margolin; Keitaro Matsuo; Kenneth Muir; Heli Nevanlinna; Paolo Peterlongo; Katri Pylkäs; Suleeporn Saajrang; Caroline Seynaeve; Chen-Yang Shen; Xiao-Ou Shu; Melissa C Southey; Anthony Swerdlow; Soo-Hwang Teo; Rob A E M Tollenaar; Thérèse Truong; Chiu-Chen Tseng; Alexandra J van den Broek; Carolien H M van Deurzen; Robert Winqvist; Anna H Wu; Cheng Har Yip; Jyh-Cherng Yu; Wei Zheng; Roger L Milne; Paul D P Pharoah; Douglas F Easton; Marjanka K Schmidt; Montserrat Garcia-Closas; Jenny Chang-Claude; Diether Lambrechts; Patrick Neven Journal: Breast Cancer Res Date: 2017-11-07 Impact factor: 6.466